Clinical Trial Update: Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cetuximab plus tislelizumab and chemotherapy for unresectable locally advanced head and neck squamous cell carcinoma, currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Conditions: LA HNSCC | Phase 2 | Status: RECRUITING